These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 1407434)
1. Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells. Kondo S; Miyatake S; Kikuchi H; Oda Y; Iwasaki K; Ohyama K; Namba Y Neurosurgery; 1992 Sep; 31(3):534-40. PubMed ID: 1407434 [TBL] [Abstract][Full Text] [Related]
2. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells. de Fries RU; Golub SH J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500 [TBL] [Abstract][Full Text] [Related]
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma-induced alterations of monocyte susceptibility to lysis by autologous lymphokine-activated killer (LAK) cells. Djeu JY; Blanchard DK Int J Cancer; 1988 Sep; 42(3):449-54. PubMed ID: 3138195 [TBL] [Abstract][Full Text] [Related]
5. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1. Triozzi PL; Eicher DM; Smoot J; Rinehart JJ Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453 [TBL] [Abstract][Full Text] [Related]
6. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma. Blanchard DK; Djeu JY J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557 [TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma induces a decrease in the susceptibility of human glioma cells to lysis by lymphokine-activated killer cells. Yin D; Kondo S; Takeuchi J; Morimura T; Nakatsu S; Oda Y; Kikuchi H Neurosurgery; 1994 Jul; 35(1):113-8. PubMed ID: 7936131 [TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells. Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960 [TBL] [Abstract][Full Text] [Related]
9. Target cell membrane modification and susceptibility to lymphokine-activated killer cell-mediated lysis. II. Sodium periodate has a differential effect on the lysis of human and murine tumor cells. Midis GP; Gupta VK; Fabian DF; Lefor AT J Surg Res; 1994 Feb; 56(2):146-54. PubMed ID: 8121171 [TBL] [Abstract][Full Text] [Related]
10. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Mizutani Y; Bonavida B; Nio Y; Yoshida O Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609 [TBL] [Abstract][Full Text] [Related]
11. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355 [TBL] [Abstract][Full Text] [Related]
12. Decreased susceptibility of lined human gliosarcoma cells to lymphokine-activated killer cell cytolysis by gamma-interferon treatment. Miyatake S; Kikuchi H; Oda Y; Nishioka T; Takahashi J; Kondoh S; Matsumoto M; Yamasaki T; Iwasaki K; Aoki T Cancer Res; 1990 Feb; 50(3):596-600. PubMed ID: 2137025 [TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma reduces the sensitivity of cultured and fresh human tumor cells to lysis by lymphokine-activated killer cells. de Fries RU; Golub SH Nat Immun Cell Growth Regul; 1988; 7(2):65-76. PubMed ID: 3137461 [TBL] [Abstract][Full Text] [Related]
14. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells. Grönberg A; Ferm M; Tsai L; Kiessling R Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094 [TBL] [Abstract][Full Text] [Related]
15. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells. Naganuma H; Kiessling R; Patarroyo M; Hansson M; Handgretinger R; Grönberg A Int J Cancer; 1991 Feb; 47(4):527-32. PubMed ID: 1671670 [TBL] [Abstract][Full Text] [Related]
16. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma. Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474 [TBL] [Abstract][Full Text] [Related]
17. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity. Jabrane-Ferrat N; Calvo F; Faille A; Lagabrielle JF; Boisson N; Quillet A; Fradelizi D Br J Cancer; 1990 Apr; 61(4):558-62. PubMed ID: 2109997 [TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations. Kaufmann Y; Davidsohn J; Levanon M; Icekson I; Revel M; Ramot B Clin Immunol Immunopathol; 1991 Feb; 58(2):278-88. PubMed ID: 1898716 [TBL] [Abstract][Full Text] [Related]
19. [Immunomodulatory effects of interferons on target human gliosarcoma cells in the tumor-specific CTL- and LAK-mediated cytolysis]. Miyatake S; Kondou S; Aoki T; Iwasaki K; Ohyama K; Ootsuka S; Oda Y; Kikuchi H No Shinkei Geka; 1991 Nov; 19(11):1053-9. PubMed ID: 1762655 [TBL] [Abstract][Full Text] [Related]
20. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms. Bean P; Mazumder A Immunobiology; 1992 Jun; 185(1):63-77. PubMed ID: 1398742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]